Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Current Opinion in Investigational Drugs (London, England : 2000)|February 7, 2004
Raf pathway inhibitors in oncologyGideon Bollag, Scott Freeman, John F Lyons, et al.
British Journal of Cancer|September 28, 2016
Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespibAurelie Courtin, Tomoko Smyth, Keisha Hearn, et al.
Molecular Cancer Therapeutics|April 1, 2010
AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samplesMatthew S Squires, Laurence Cooke, Victoria Lock, et al.
Communications Biology|April 24, 2025
The identification of functional regions of MEK1 using CRISPR tiling screensZhiqiang Zhang, Barbara Abreu, Jessica L Brothwood, et al.
Molecular Cancer Therapeutics|January 29, 2009
Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell linesMatthew S Squires, Ruth E Feltell, Nicola G Wallis, et al.
Cancer Research|January 9, 2003
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cellsM Jane Arboleda, John F Lyons, Fairooz F Kabbinavar, et al.
Cancer Research Communications|May 10, 2024
Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell LymphomaGeorge A Ward, Zhiqiang Zhang, Simone Jueliger, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2016
Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumourAndrew J Wagner, Mark Agulnik, Michael C Heinrich, et al.
Blood|June 16, 2010
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cellsRuriko Tanaka, Matthew S Squires, Shinya Kimura, et al.
British Journal of Haematology|May 29, 2010
AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disordersMark A Dawson, Jayne E Curry, Kelly Barber, et al.
Pageof 2